ResMed (RMD)
Builds connected sleep-apnea devices, masks, ventilators, and home-care software.
Something off on this page? Send us feedback.
Sells connected positive airway pressure devices, masks, home ventilators, diagnostics, and care-management software, with most revenue coming from sleep and breathing devices and recurring accessories. Cloud monitoring links patients and providers, while reimbursement, medical-device regulation, and component supply shape the business.
Designs and sells positive airway pressure devices, masks, accessories, home ventilators, diagnostics, and connected software for sleep apnea and other respiratory disorders. The Sleep and Breathing Health segment includes AirSense and AirCurve therapy devices, AirFit and AirTouch masks, AirView clinician monitoring, and myAir patient support, sold in more than 140 countries.
Connects therapy hardware to remote monitoring, settings changes, troubleshooting, and patient coaching. Residential Care Software provides Brightree and MEDIFOX DAN workflow systems to home-medical-equipment and residential care providers; MatrixCare remains in the segment pending its agreed sale.
Sells primarily through home-medical-equipment providers, distributors, sleep clinics, and health systems. Demand depends on medical-device approvals, quality compliance, and third-party reimbursement, while some configured device components come from single-source suppliers.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 15, 2026 | RBC Capital | Upgrade | Target: $234 | Target: $262 |
| Aug 31, 2026 | KeyBanc | Reiterate | Rating: —Target: $255 | Target: $267 |
| Aug 19, 2026 | Redburn Partners | Target | Target: — | Target: $230 |
| Aug 7, 2026 | Robert W. Baird | Target | Target: $225 | Target: $213 |
| Aug 7, 2026 | Keybanc | Reiterate | Rating: —Target: $266 | Target: $255 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.47B · Total debt $825.9M · Total assets $8.97B · Shareholders' equity $6.59B
- Revenue
- $1.46B
- Operating income
- $448.7M
- Net income
- $383.4M
HistoryDividendAnnual yield
| Institutions | 69.73% | 101.14M shares | |
|---|---|---|---|
| 919 holders · as of Jun 30, 2026 | |||
| Insiders | 0.51% | 746.6K shares | |
| 16 holders · as of Sep 10, 2026 | |||
| Other | 29.76% | 43.17M shares | |
| remainder | |||
145.06M company shares as of Sep 17, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.49% | 12.32M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.53% | 9.47M | as of Jun 30, 2026 |
WCM Investment Management, LLCInstitution | 6.24% | 9.05M | filed Feb 10, 2022 |
Vanguard Portfolio Management LLCInstitution | 5.46% | 7.91M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.61% | 6.68M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | Michael J. Farrell | director, officer: Chairman and CEO | −4,991 | $222.44 |
| Sep 2, 2026 | Peter C. Farrell | director | −970 | $234.73 |
| Aug 7, 2026 | Michael J. Farrell | director, officer: Chairman and CEO | −4,991 | $205.69 |
| Aug 5, 2026 | Peter C. Farrell | director | −8,000 | $225.00 |
| Jul 7, 2026 | Michael J. Farrell | director, officer: Chairman and CEO | −4,991 | $218.55 |
- Philips (ADR)
Primary device rival globally; US new-device sales blocked by FDA consent decree.
- Five Point
Named primary rival in OSA masks and hospital respiratory; $2B+ FY2025 revenue.
- Inspire Medical Systems
Implantable nerve stimulator for CPAP-intolerant OSA patients; $912M FY2025.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ResMed | $224.71 | +0.49% | $32.44B | 21.5 | 18.5 | 5.7 | +8.6% |
| Philips (ADR) | $24.95 | +0.20% | $24.34B | 18.7 | 13.0 | 1.2 | −2.8% |
| Five Point | $4.91 | −0.30% | $349.8M | 14.1 | — | 3.0 | +157.8% |
| Inspire Medical Systems | $73.14 | −3.41% | $2.19B | 16.4 | 56.3 | 2.4 | −7.6% |
| Median | 16.4 | 34.6 | 2.4 | −2.8% |